Herpesviridae infectious disease

This study tests a new chickenpox vaccine called NBP608 in about 780 children aged 1 to 12 years. The vaccine is compared to licensed vaccines to see how well it triggers immunity and if it is safe. Children receive one or two shots, and researchers monitor their immune response …

This study tests a new chickenpox vaccine in 300 healthy children aged 1 to 12 years. All children will receive one dose of the vaccine. Researchers will check if the vaccine triggers a strong immune response and is safe to use.

This early-stage trial is testing a new mRNA vaccine called VXCO-102 against Epstein-Barr virus (EBV) in 45 healthy adults aged 18 to 25. The main goal is to check if the vaccine is safe and triggers an immune response. EBV is a common virus that can cause mononucleosis and is li…

This study tests a new vaccine that protects against measles, mumps, rubella, and chickenpox (MMRV) in healthy children aged 15 months to 6 years. It compares the new vaccine to an already approved one (ProQuad) to see if it works as well and is safe. About 1,200 children will re…

This study tests a new mRNA vaccine called SYS6017 to prevent shingles, a painful rash caused by the chickenpox virus. About 800 healthy adults aged 40 and older will receive either the new vaccine, a placebo, or an existing shingles vaccine. Researchers will check how well the v…

This phase 2 trial tests a new mRNA vaccine called IN001 for preventing shingles in healthy adults aged 50 to 79. Researchers will compare three dose levels of IN001 against the existing Shingrix vaccine to see how safe and effective they are. The study involves 480 participants …

This Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assign…

This study tests a drug called Sintilimab, which is normally used for cancer, to see if it can help people with HIV who have infections that won't go away with standard treatment. The drug works by 'waking up' exhausted immune cells. Fifty adults with HIV and a hard-to-treat infe…

This study tests whether adjusting the dose of anti-rejection drugs can help control CMV infection in organ transplant recipients. About 100 adults who have had a kidney, liver, heart, lung, or pancreas transplant and now have a CMV infection will take part. Researchers will moni…

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This study tests whether oral valganciclovir or ganciclovir eye drops can reduce the virus causing eye inflammation and prevent flare-ups. About 117 adults with CMV anterior uveitis will receive either antiviral treatment or placebo for 7 days, then some continue for 12 months. T…

This early-stage trial tests whether treating a donor kidney with a drug called SYN002 before transplant can safely reduce the risk of passing cytomegalovirus (CMV) to the recipient. About 12 adults waiting for a kidney transplant will receive a treated organ. The main goal is to…

This study compares a 4-month course of antiviral medication (ganciclovir or valganciclovir) against the standard 6-month course for babies born with moderate-to-severe congenital CMV infection. The goal is to see if the shorter treatment works just as well at preventing long-ter…

This study tests a scoring system that uses immune system recovery to decide how long patients should take antiviral medicine after a stem cell transplant. The goal is to prevent a common virus called CMV from causing infection. About 1,114 transplant recipients will take part to…

This study tests whether valganciclovir, a drug that stops CMV from multiplying, can safely lower CMV levels in the blood of people with advanced HIV. About 130 adults and adolescents with very weak immune systems will be randomly assigned to take either valganciclovir or a place…

This phase 2 trial tests a new drug called zuberitamab as a first-line treatment for EBV infection in 20 adults who have had a stem cell transplant. EBV can cause a serious complication after transplant, and current treatments don't work for everyone. Zuberitamab is designed to b…

This study tests whether adding immune cells from a family donor to standard antiviral drugs can help children and young adults clear stubborn adenovirus or cytomegalovirus infections after a stem cell transplant. About 69 participants will be randomly assigned to receive either …

This study tests two different drug combinations to prevent cytomegalovirus (CMV) infection in kidney transplant patients who are at high risk. Thirty adults who are CMV-positive before transplant will receive either tacrolimus plus mTOR inhibitors with early antiviral treatment,…

This study tests whether the antiviral drug aciclovir (or its pill form valacyclovir) works better than a placebo for treating meningitis caused by the herpes simplex virus type 2 (HSV-2). About 150 adults with confirmed HSV-2 meningitis will receive either the drug or a placebo,…

This study will test a new blood test that looks for tiny molecules called miRNAs to detect HCMV infection earlier in people who have received a stem cell transplant. The standard DNA test can miss early signs, so researchers hope this new method will give doctors a head start. A…

This phase 3 trial tests whether adding daily calcitonin injections to standard shingles treatment can prevent postherpetic neuralgia, a painful nerve condition that can last for months or years. Researchers will enroll 168 adults aged 50 and older who have had a shingles rash fo…

This study tests whether the drug rituximab can safely clear Epstein-Barr virus (EBV) from the blood of people who have received a solid organ transplant. High levels of EBV can lead to a serious cancer called post-transplant lymphoproliferative disorder (PTLD). The trial will en…

This study tests if letermovir works as well as valganciclovir in preventing CMV infection in 300 kidney transplant patients who are CMV-positive. Both drugs are given for 90 days after transplant. Researchers will also check if letermovir is easier to tolerate and how long it ta…

This study tests whether a short course of the steroid prednisolone can prevent paradoxical immune reconstitution inflammatory syndrome (IRIS) in people with AIDS who have low CD4 counts and are starting HIV treatment. About 131 participants will receive either prednisolone or no…

This study tests a new shingles vaccine in 135 healthy adults aged 50 and older. Researchers will compare the immune response and safety of the new vaccine against an existing one to find the best dose. The goal is to prevent shingles, a painful rash caused by the chickenpox viru…

This early-stage study tests whether specially prepared immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 participants will receive the cells and be monitored for side effects and infection. …

This study tests whether taking acyclovir daily can prevent herpes simplex outbreaks in people with autoimmune rheumatic diseases like lupus or rheumatoid arthritis. 62 participants will receive either acyclovir or a placebo for 12 months and be monitored for 24 months total. The…

This study tests whether an extra dose of the shingles vaccine (Shingrix) can boost immunity in people who have had a solid-organ transplant, like a kidney or liver. About 30% of transplant patients still get shingles after the standard two-dose vaccine, likely due to immune-supp…

This study tests whether an IDO-1 inhibitor can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant recipients who have never had EBV but receive a kidney from an EBV-positive donor. Nine participants will receive either the drug or a placebo for 28 days, along…

This study looks at whether the shingles vaccine can prevent shingles and improve survival in 500 lung cancer patients. Participants will either receive the vaccine or not, and researchers will track shingles cases and survival rates over time. The goal is to see if the vaccine o…

This study tests a special gel applied to the skin to see if it can quickly reduce pain from shingles. Thirty adults with shingles-related pain will receive a single application of the gel. Researchers will measure pain levels before and after application, focusing on relief with…

This study tests whether dexamethasone palmitate, a steroid, can better relieve shingles pain and prevent long-term nerve pain compared to standard care. About 954 adults with shingles rash and severe pain will receive the drug by injection or infusion. Researchers will track pai…

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This study will follow 1000 kidney transplant patients for one year to see if monthly blood tests for certain viruses (CMV, BK, and TTV) can help predict and prevent serious infections and kidney damage. The goal is to learn how the body's immune system and virus levels relate to…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…

This study looks at whether measuring two new viral markers (CMV-RNA and TTV-DNA) in the blood can give a clearer picture of CMV infection in patients who have had a stem cell transplant and are taking the drug letermovir to prevent CMV. Researchers will track 290 adult transplan…

This study follows 123 stem cell transplant patients to see if measuring their immune response to CMV after stopping a preventive drug (letermovir) can predict late infections. Participants will have regular blood tests up to 200 days after transplant. The goal is to learn whethe…

This study looks at how CMV (a common virus) changes the immune system in people who have had a kidney transplant. Researchers will take blood samples from 60 patients to compare immune responses in those with and without CMV infection. The goal is to understand why CMV may incre…